First GLP-1 pill approved
- The FDA approved oral semaglutide as the first GLP-1 pill specifically cleared for weight loss. (ajmc.com) - The approval creates a pill alternative to injectables like Wegovy, changing dosing convenience for patients. (ajmc.com) - Coverage gaps and variable patient responses mean convenience may not equal access or universal effectiveness yet. ( )
A GLP-1 drug tells the body to feel full sooner and empty the stomach more slowly; now the Food and Drug Administration has cleared the first pill version for weight loss in adults. (fda.gov) The drug is Wegovy tablet, an oral form of semaglutide made by Novo Nordisk, approved in a 25-milligram once-daily dose for adults with obesity or with overweight plus at least one weight-related condition. (fda.gov) The label also says the tablet can be used to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight, matching a key use already attached to injectable Wegovy. (fda.gov) Until this approval, people seeking a GLP-1 drug specifically cleared for chronic weight management in the United States mostly got weekly injections such as Wegovy, while oral semaglutide was sold as Rybelsus for type 2 diabetes. (fda.gov; fda.gov) The approval rested on the phase 3 OASIS 4 trial, which enrolled 307 adults without diabetes and compared oral semaglutide 25 milligrams with placebo over 64 weeks. Participants on the drug lost 13.6% of body weight on average in the main analysis, versus 2.2% with placebo. (ajmc.com) In a stricter analysis of participants who stayed on treatment as planned, average weight loss reached 16.6%, and about one-third of treated patients lost at least 20% of body weight. (appliedclinicaltrialsonline.com) The side effects looked familiar from injectable semaglutide: nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, indigestion, dizziness, bloating, belching, low blood sugar in some patients, and gas all appear on the Wegovy tablet label. (fda.gov) A pill changes the routine but not the rules of access. Novo Nordisk said at approval that it was preparing a U.S. launch in early January 2026, while insurers have continued to vary widely on obesity-drug coverage. (prnewswire.com; ajmc.com) The science behind the pill is not new: Novo Nordisk has sold oral semaglutide for diabetes since 2019, and the company says the weight-loss approval extends that same oral delivery approach to a higher-dose obesity drug. (novonordisk.com) The immediate change is simple: patients who qualify for semaglutide for weight loss now have a choice between a weekly shot and a daily tablet, with the same questions about cost, coverage, side effects, and staying on treatment still unresolved. (fda.gov; ajmc.com)
